VAUGHAN, Ontario / Mar 26, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.
Conference Call Details
Date: | Wednesday, April 30, 2025 | ||
Time: | 8 a.m. ET | ||
Webcast: | |||
Participant Event Dial-in: | +1 (888) 506-0062 (North America) +1 (973) 528-0011 (International) | ||
Participant Access Code: | 810276 | ||
Replay Dial-in: | +1 (877) 481-4010 (North America) +1 (919) 882-2331 (International) | ||
Replay Passcode: | 51713 (replay available until May 14, 2025) |
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.
© 2025 Bausch + Lomb.
| Last Trade: | US$13.88 |
| Daily Change: | -0.32 -2.25 |
| Daily Volume: | 385,989 |
| Market Cap: | US$4.910B |
June 04, 2025 May 21, 2025 May 07, 2025 April 30, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
